Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias

Completed · Phase 2 · Has a placebo group

Conditions studied: Premature Atrial Contraction

In brief

The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).

Key facts

Study ID

NCT02837328

Run by

University of Minnesota

People needed

59

Starts

2017-03-01

Expected to finish

2017-09-15

Last updated by the study team

2019-11-01

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 55 and older
• Ability to speak English
• Availability to attend baseline and follow-up visit approximately 12 weeks after baseline

You may not qualify if…

• Prior history of heart disease (coronary heart disease, heart failure, atrial fibrillation), stroke, severe renal disease
• Use of type I and III antiarrhythmics or digoxin
• Current use of magnesium supplements
• Any prior history of allergy or intolerance to magnesium
• Prior history of inflammatory bowel disease or any severe gastrointestinal disorder

Where it is running

• University of Minnesota - Twin Cities — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.